SMO and cancer: An exploratory study conducted by Leandro M. Colli et al. using cancer genomic data sets for somatic mutation profiles indicated that a significant proportion of SMO mutated patients could be benefited from a combination of immunotherapy with targeted therapy considering the mutational burden [136].